SILVER SPRING, Md. – Can the development of antimicrobials and susceptibility tests be coordinated more effectively? Yes, according to attendees of an FDA workshop Thursday on challenges and opportunities for getting clearance for antimicrobial susceptibility tests (ASTs) shortly after antimicrobial drug approval.

Boston Scientific (NYSE: BSX) has agreed to buy Endochoice Holdings, an Alpharetta, Ga.-based company focused on endoscopy, in a deal valued at about $210 million. Endochoice (NYSE: GI) develops single-use devices, such as resection and retrieval devices, needles, graspers and infection control kits. The company also is a player in pathology services and imaging technologies. Upon the completion of the deal, Endochoice will become part of Marlborough, Mass.-based Boston Scientific's endoscopy business. The companies hope to wrap up the transaction before the end of the year. "The addition of Endochoice products and services to our...

Boston Scientific (NYSE: BSX) has agreed to buy Endochoice Holdings, an Alpharetta, Ga.-based company focused on endoscopy, in a deal valued at about $210 million.

Staff Writer WASHINGTON – Next-generation sequencing-based tests are taking center stage on Friday, with the FDA seeking the public's feedback on two draft guidance documents intended to support President Barack Obama's Precision Medicine Initiative.

Another tech titan is partnering with a life sciences company to help patients with a difficult-to-treat disease. This time, Teva Pharmaceutical Industries Ltd. and Santa Clara, Calif.-based Intel are teaming up to develop a wearable device intended to continuously monitor and analyze Huntington's disease symptoms.

A court battle between Alere Inc. and its potential acquirer Abbott Labs could be inching towards a resolution. The two sides agreed last week to work with a mediator to resolve the dispute, which has landed in the Delaware Chancery Court.

Kalamazoo, Mich.-based Stryker Corp. just scored a win after the FDA gave the green light for marketing two Trevo clot retrieval devices as first-line treatments to reduce disability in patients experiencing ischemic stroke. It is the first therapy to receive the front-line designation in this indication in 20 years, the company said.